DOC-2/DAB2 Interacting Protein Status in High-Risk Prostate Cancer Correlates With Outcome for Patients Treated With Radiation Therapy

被引:8
|
作者
Jacobs, Corbin [1 ]
Tumati, Vasu [1 ]
Kapur, Payal [2 ]
Yan, Jingsheng [3 ]
Hong, David [1 ]
Bhuiyan, Manzerul [1 ]
Xie, Xian-Jin [3 ]
Pistenmaa, David [1 ,5 ]
Yu, Lan [1 ]
Hsieh, Jer-Tsong [4 ,5 ]
Saha, Debabrata [1 ,5 ]
Kim, D. W. Nathan [1 ,5 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[4] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[5] Simmons Canc Ctr, Dallas, TX USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 89卷 / 04期
关键词
DAB2IP GENE-EXPRESSION; GROUP PROTOCOL 92-02; PHASE-III TRIAL; ANDROGEN SUPPRESSION; EZH2; EXPRESSION; DOWN-REGULATION; RADIOTHERAPY; PROGRESSION; MECHANISM; ONCOLOGY;
D O I
10.1016/j.ijrobp.2014.03.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This pilot study investigates the role of DOC-2/DAB2 Interacting Protein (DAB2IP) and enhancer of zeste homolog 2 (EZH2) as prognostic biomarkers in high-risk prostate cancer patients receiving definitive radiation therapy. Methods and Materials: Immunohistochemistry was performed and scored by an expert genitourinary pathologist. Clinical endpoints evaluated were freedom from biochemical failure (FFBF), castration resistance-free survival (CRFS), and distant metastasis-free survival (DMFS). Log-rank test and Cox regression were used to determine significance of biomarker levels with clinical outcome. Results: Fifty-four patients with high-risk prostate cancer (stage >= T3a, or Gleason score >= 8, or prostate-specific antigen level >= 20 ng/mL) treated with radiation therapy from 2005 to 2012 at our institution were evaluated. Nearly all patients expressed EZH2 (98%), whereas 28% of patients revealed DAB2IP reduction and 72% retained DAB2IP. Median follow-up was 34.0 months for DAB2IP-reduced patients, 29.9 months for DAB2IP-retained patients, and 32.6 months in the EZH2 study. Reduction in DAB2IP portended worse outcome compared with DAB2IP-retained patients, including FFBF (4-year: 37% vs 89%, P=.04), CRFS (4-year: 50% vs 90%, P=.02), and DMFS (4-year: 36% vs 97%, P=.05). Stratified EZH2 expression trended toward significance for worse FFBF and CRFS (P=.07). Patients with reduced DAB2IP or highest-intensity EZH2 expression exhibited worse FFBF (4-year: 32% vs 95%, P=.02), CRFS (4-year: 28% vs 100%, P<.01), and DMFS (4-year: 39% vs 100%, P=.04) compared with the control group. Conclusion: Loss of DAB2IP is a potent biomarker that portends worse outcome despite definitive radiation therapy for patients with high-risk prostate cancer. Enhancer of zeste homolog 2 is expressed in most high-risk tumors and is a less potent discriminator of outcome in this study. The DAB2IP status in combination with degree of EZH2 expression may be useful for determining patients with worse outcome within the high-risk prostate cancer population. (C) 2014 Elsevier Inc.
引用
收藏
页码:729 / 735
页数:7
相关论文
共 50 条
  • [31] Outcome in intermediate or high risk prostate cancer patients receiving radiation dose and hormone therapy
    Karlsdottir, Asa
    Muren, Ludvig Paul
    Wentzel-Larsen, Tore
    Johannessen, Dag C.
    Haukaas, Svein Andreas
    Halvorsen, Ole Johan
    Dahl, Olav
    ACTA ONCOLOGICA, 2009, 48 (06) : 874 - 881
  • [32] Monitoring of Circulating Tumor Cells in Patients With High-Risk Nonmetastatic Prostate Cancer Treated With Radiation Therapy and Hormones: Preliminary Data of an Observational Prospective Phase 2 Study
    Zapatero, A.
    CaamaNo, A. Gomez
    Rodriguez, M. D. L. A. Cabeza
    Muinelo-Romay, L.
    de Vidales C, C. Martin
    Abalo, A.
    Castro, A. Carballo
    Crespo, P. Calvo
    Higuero, P. Peleteiro
    Cruz-Conde, A.
    Olivier, C.
    Mateos, L. Leon
    Murillo, M. T.
    Piris, L. Vega
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E280 - E280
  • [33] Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodes
    Faria, S.
    Duclos, M.
    Cury, F.
    Patrocinio, H.
    Souhami, L.
    CANCER RADIOTHERAPIE, 2024, 28 (02): : 159 - 163
  • [34] Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy
    Patel, Mira A.
    Kollmeier, Marisa
    McBride, Sean
    Gorovets, Daniel
    Varghese, Melissa
    Chan, Luanna
    Knezevic, Andrea
    Zhang, Zhigang
    Zelefsky, Michael J.
    RADIOTHERAPY AND ONCOLOGY, 2019, 140 : 34 - 40
  • [35] Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Risk Stratification for Intermediate- and High-Risk Patients
    Katz, A.
    Kang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E250 - E250
  • [36] High-risk prostate cancer treated with a stereotactic body radiation therapy boost following pelvic nodal irradiation
    Lischalk, Jonathan W.
    Akerman, Meredith
    Repka, Michael C.
    Sanchez, Astrid
    Mendez, Christopher
    Santos, Vianca F.
    Carpenter, Todd
    Wise, David
    Corcoran, Anthony
    Lepor, Herbert
    Katz, Aaron
    Haas, Jonathan A.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [37] Interval to Biochemical Failure Predicts Clinical Outcomes in Patients With High-Risk Prostate Cancer Treated by Combined-Modality Radiation Therapy
    Shilkrut, Mark
    McLaughlin, P. William
    Merrick, Gregory S.
    Vainshtein, Jeffrey M.
    Feng, Felix Y.
    Hamstra, Daniel A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (04): : 721 - 728
  • [38] Intermediate versus short-course hormone therapy and mortality in men with high-risk prostate cancer treated with radiation therapy
    Nanda, Akash
    Chen, Ming-Hui
    Moran, Brian Joseph
    Braccioforte, Michelle H.
    D'Amico, Anthony Victor
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [39] Neoadjuvant docetaxel and estramustine followed by radical prostatectomy or radiation therapy for patients with high-risk prostate cancer
    Stefaniak, H
    Wallen, E
    Baggstrom, M
    Godley, P
    Rosenman, J
    Goyal, L
    Whang, Y
    Pruthi, RS
    JOURNAL OF UROLOGY, 2005, 173 (04): : 190 - 190
  • [40] Risk Factors Predicting Failure and Prostate Cancer Mortality in High Risk Prostate Cancer Patients Treated with Definitive External Beam Radiation Therapy
    Nguyen, Q.
    Levy, L. B.
    Lee, A. K.
    Choi, S.
    Frank, S. J.
    Hoffman, K.
    McGuire, S.
    Kuban, D. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S125 - S125